Aliases & Classifications for Morbid Obesity

MalaCards integrated aliases for Morbid Obesity:

Name: Morbid Obesity 38 12 29 14
Obesity, Morbid 42 69
Severe Obesity 12
Obesity Morbid 52

Classifications:



External Ids:

Disease Ontology 12 DOID:11981
ICD9CM 35 278.01
MeSH 42 D009767
NCIt 47 C34858
UMLS 69 C0028756

Summaries for Morbid Obesity

MalaCards based summary : Morbid Obesity, also known as obesity, morbid, is related to intussusception and myocardial infarction, and has symptoms including overweight and obesity, metabolically benign. An important gene associated with Morbid Obesity is PPARG (Peroxisome Proliferator Activated Receptor Gamma), and among its related pathways/superpathways are Peptide ligand-binding receptors and Glucose / Energy Metabolism. The drugs Dexmedetomidine and Hydroxocobalamin have been mentioned in the context of this disorder. Affiliated tissues include liver, kidney and testes, and related phenotypes are adipose tissue and homeostasis/metabolism

Related Diseases for Morbid Obesity

Diseases related to Morbid Obesity via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 180)
id Related Disease Score Top Affiliating Genes
1 intussusception 29.9 ALB CCK
2 myocardial infarction 28.5 ADIPOQ ALB CRP GHRL INS RETN
3 morbid obesity and spermatogenic failure 12.3
4 obesity, morbid, due to leptin receptor deficiency 11.2
5 obesity, morbid, due to leptin deficiency 11.2
6 obesity 10.9
7 obesity susceptibility, ghrl-related 10.8 ADRB3 MC4R
8 chronic fungal otitis externa 10.8 CRP INS
9 obesity, mc4r-related 10.7 GHRL MC4R
10 achard thiers syndrome 10.7 ADIPOQ PPARG
11 lipodystrophy, familial partial, type 2 10.7 INS LEP
12 myh-9 related disease 10.7 INS LEP
13 neurogenic arthropathy 10.6 ADIPOQ INS LEP
14 mucinoses 10.6 ADIPOQ INS LEP
15 lipoic acid biosynthesis defects 10.6 LEP LEPR
16 acquired hypoprothrombinemia 10.6 ADIPOQ LEP RETN
17 leigh syndrome with leukodystrophy 10.6 ADIPOQ LEP RETN
18 scleredema adultorum 10.6 ADIPOQ LEP RETN
19 corpus callosum agenesis of blepharophimosis robin type 10.5 ADIPOQ LEP RETN
20 gaucher's disease 10.5 ADRB3 CRP INS
21 lissencephaly 10.5 INS LEP PPARG
22 ovarian clear cell malignant adenofibroma 10.5 ADIPOQ CRP INS
23 acquired polycythemia 10.5 CCK CRP
24 idiopathic juxtafoveal retinal telangiectasia 10.5 ADIPOQ INS PPARG
25 skin meningioma 10.5 GHRL INS LEP
26 myotonic cataract 10.4 CRP INS
27 exostosis 10.4 GHRL INS LEP
28 dientamoebiasis 10.4 ADIPOQ INS LEP LEPR
29 ragweed sensitivity 10.4 ADIPOQ CRP PPARG
30 intestinal volvulus 10.4 INS PYY
31 capillary leak syndrome 10.4 ALB CRP
32 hypomagnesemia 3, renal 10.3 ADIPOQ INS LEP PPARG
33 cataract 10.3 ALB INS
34 colonic disease 10.3 CRP HCRT LEP
35 mature gastric teratoma 10.3 ADIPOQ INS LEP PPARG
36 calcinosis 10.2 ALB CRP INS
37 endometrial clear cell adenocarcinoma 10.2 ALB CRP GHRL
38 hyperinsulinemic hypoglycemia, familial, 4 10.2 ADIPOQ GHRL INS PPARG
39 myelophthisic anemia 10.2 ADIPOQ CRP INS PPARG
40 chondroma 10.2 CCK CRP INS LEP
41 cataract, autosomal dominant congenital 4 10.2 INS PPARG
42 exophthalmic ophthalmoplegia 10.2 ADIPOQ ALB LEP LEPR
43 speech and communication disorders 10.1 ALB CRP
44 chronic myelomonocytic leukemia 10.1 ALB CRP INS LEP
45 antidepressant type abuse 10.1 ADIPOQ ADRB3 INS LEP RETN
46 fissured tongue 10.1 ALB CCK INS
47 mediastinum leiomyoma 10.1 ALB CRP GHRL LEP
48 immunodeficiency 19 10.1 INS LPL
49 lymphoblastic lymphoma 10.1 ADIPOQ ALB INS LEP
50 peripheral artery disease 10.1 ADIPOQ ALB CRP INS

Graphical network of the top 20 diseases related to Morbid Obesity:



Diseases related to Morbid Obesity

Symptoms & Phenotypes for Morbid Obesity

UMLS symptoms related to Morbid Obesity:


overweight, obesity, metabolically benign

MGI Mouse Phenotypes related to Morbid Obesity:

44 (show all 12)
id Description MGI Source Accession Score Top Affiliating Genes
1 adipose tissue MP:0005375 10.39 ADIPOQ ADRB3 CEP19 FABP2 FTO GHRL
2 homeostasis/metabolism MP:0005376 10.38 ADIPOQ ADRB3 ALB CCK CEP19 CRP
3 behavior/neurological MP:0005386 10.34 ADIPOQ ADRB3 CCK CEP19 FTO GHRL
4 growth/size/body region MP:0005378 10.28 PPARG PYY ADIPOQ ADRB3 CEP19 FABP2
5 endocrine/exocrine gland MP:0005379 10.16 ADIPOQ ADRB3 ALB CCK FTO GHRL
6 cardiovascular system MP:0005385 10.13 ADIPOQ CRP HCRT INS LEP LEPR
7 immune system MP:0005387 10.07 LEPR MC3R MC4R PPARG RETN ADIPOQ
8 liver/biliary system MP:0005370 10.06 PPARG RETN ADIPOQ ALB FABP2 FTO
9 muscle MP:0005369 9.86 ADIPOQ ALB HCRT INS LEP LEPR
10 neoplasm MP:0002006 9.63 ADIPOQ ALB LEP LEPR MC4R PPARG
11 renal/urinary system MP:0005367 9.56 ADIPOQ ALB FABP2 FTO INS LEP
12 skeleton MP:0005390 9.28 FTO INS LEP LEPR MC3R MC4R

Drugs & Therapeutics for Morbid Obesity

Drugs for Morbid Obesity (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 360)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3 76631-46-4, 113775-47-6 68602 5311068 56032
2
Hydroxocobalamin Approved Phase 4,Phase 2,Phase 3 13422-51-0 11953898 5460373 44475014
3
Morphine Approved, Investigational Phase 4,Phase 2,Phase 3 57-27-2 5288826
4
Acetaminophen Approved Phase 4,Phase 3,Phase 1,Early Phase 1 103-90-2 1983
5
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
6
Dalteparin Approved Phase 4 9005-49-6
7
Heparin Approved, Investigational Phase 4,Phase 1,Phase 2 9005-49-6 772 46507594
8 Nadroparin Approved Phase 4 9041-08-1
9
Benzocaine Approved Phase 4,Phase 3,Phase 2 1994-09-7, 94-09-7 2337
10
Rocuronium Approved Phase 4,Phase 2 119302-91-9, 143558-00-3 441290
11
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 2078-54-8 4943
12
Liraglutide Approved Phase 4 204656-20-2 44147092
13
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3 437-38-7 3345
14
Ketamine Approved, Vet_approved Phase 4,Phase 3 6740-88-1 3821
15
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1 657-24-9 14219 4091
16
Micafungin Approved, Investigational Phase 4 235114-32-6 3081921 477468
17
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
18
chenodeoxycholic acid Approved Phase 4,Phase 2,Phase 1 474-25-9 10133
19
Ursodeoxycholic acid Approved, Investigational Phase 4 128-13-2 31401
20
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7 4594 9579578
21
Iron Approved Phase 4,Phase 2,Phase 3 7439-89-6 23925
22
Oxycodone Approved, Illicit, Investigational Phase 4,Phase 3 76-42-6 5284603
23
Ibuprofen Approved Phase 4 15687-27-1 3672
24
Anidulafungin Approved, Investigational Phase 4 166663-25-8 166548
25
Cefazolin Approved Phase 4 25953-19-9 656510 33255
26
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
27
Anastrozole Approved, Investigational Phase 4 120511-73-1 2187
28
Chlorhexidine Approved, Vet_approved Phase 4 55-56-1 9552079 2713
29
Coal tar Approved Phase 4 8007-45-2
30
Octreotide Approved, Investigational Phase 4 83150-76-9 383414 6400441
31
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
32
Verapamil Approved Phase 4 52-53-9 2520
33
Amphotericin B Approved, Investigational Phase 4 1397-89-3 14956 5280965
34
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
35
Cyanocobalamin Approved, Nutraceutical Phase 4,Phase 2,Phase 3 68-19-9 44176380
36
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3 59-30-3 6037
37
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 11103-57-4, 68-26-8 445354
38 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 2
39
Cholecalciferol Approved, Nutraceutical Phase 4,Phase 1 67-97-0 6221 10883523 5280795
40
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 1 50-14-6 5280793
41
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 1406-16-2
42
Methylene blue Investigational Phase 4,Phase 1,Phase 2 61-73-4
43 Fondaparinux Investigational Phase 4,Phase 1 104993-28-4
44 Hormones Phase 4,Phase 2,Phase 3,Phase 1
45 Adrenergic Agents Phase 4,Phase 3,Phase 1,Early Phase 1
46 Adrenergic Agonists Phase 4,Phase 3
47 Adrenergic alpha-2 Receptor Agonists Phase 4,Phase 3
48 Adrenergic alpha-Agonists Phase 4,Phase 3
49 Analgesics Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
50 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 590)

id Name Status NCT ID Phase Drugs
1 Impact of the Preservation of the Gastric Antrum in the Technique of Sleeve Gastrectomy for the Treatment of the Morbid Obesity Unknown status NCT01550601 Phase 4
2 Pharmacokinetics of Dexmedetomidine in Morbid Obesity Unknown status NCT01864187 Phase 4 Dexmedetomidine
3 Vitamin Deficiencies and Suppletion in Morbid Obesity Unknown status NCT02270749 Phase 4 Hydroxocobalamin;FitForMe vitamin B12
4 Evaluation of the Effects of Laying Early a Gastric Band on the Prevention of Morbid Obesity Randomized Checked Against Standard Management of Obesity in This Population. Unknown status NCT01700738 Phase 4
5 VAS Correlation With BMI Unknown status NCT02017314 Phase 4 Morphine
6 Laparoscopic Roux-en-Y Gastric Bypass Versus Laparoscopic Sleeve Gastrectomy Unknown status NCT00667706 Phase 4
7 Pharmacokinetics of Acetaminophen in Morbidly Obese Patients Unknown status NCT01764555 Phase 4 acetaminophen 2 g
8 CYP3A4 Metabolism Before and After Surgery Induced Weight Loss Using Midazolam as Model Drug Unknown status NCT01519726 Phase 4 Midazolam
9 Anti Xa Levels Under Two Different Regimens of Enoxaparin VTE Prophylaxis After Sleeve Gastrectomy for Morbid Obesity Unknown status NCT01970202 Phase 4 40mg Enoxaparin;60mg Enoxaparin
10 Banded Versus Conventional Laparoscopic Roux-en-Y (GABY) Unknown status NCT01015469 Phase 4
11 Prophylaxis of Venous Thromboembolism After Bariatric Surgery Unknown status NCT02295150 Phase 4 Nadroparin
12 Laparoscopic Bariatric Surgery: Impact of Deep Neuromuscular Block on Surgical Conditions Unknown status NCT02118844 Phase 4 rocuronium
13 Obesity Cohort : Medical Follow-up of Severe or Morbid Obese Patients Undergoing Bariatric Surgery Unknown status NCT02310178 Phase 4
14 Clinical Trial Between Laparoscopic Gastric Bypass and Laparoscopic Vertical Banded Gastroplasty for Morbid Obesity Completed NCT01639677 Phase 4
15 Post Implantation/Post Market Evaluation of the Swedish Adjustable Gastric Band Completed NCT00543140 Phase 4
16 Investigations on the Influence of Bariatric Surgery on the Metabolism and Absorption of Atorvastatin Completed NCT00331565 Phase 4
17 Population PK/PD of Propofol in the Morbidly Obese Patient Completed NCT00395681 Phase 4 Diprivan
18 Micafungin Pharmacokinetics in Obese Patients Completed NCT03102658 Phase 4 Micafungin
19 Garcinia Mangostana Extracts in the Management of Weight Loss Completed NCT02823561 Phase 4
20 Effects of Bile Acids on GLP-1 Secretion After Roux-en-Y Gastric Bypass Completed NCT02340247 Phase 4 Ursodeoxycholic Acid;Chenodeoxycholic Acid
21 Fondaparinux Population Pharmacokinetic to Morbid Obese Patients in Post-operatory Bariatric Surgery Completed NCT01064596 Phase 4
22 Use Of Esomeprazole In Postoperative Bariatric Surgery Patients Users And Non-Users Of Nonsteroidal Anti-Inflammatory Drugs (NSAIDS) Completed NCT00608712 Phase 4 Esomeprazole
23 The Use of Liposomated Iron After Bariatric Surgery in Patients That Are Receiving Parentheral Therapy With Iron Completed NCT02390921 Phase 4 Fisiogen Ferro Forte;Venofer
24 A Trial of the Cost Effectiveness of IV Acetaminophen in Bariatric Surgery Completed NCT02233400 Phase 4 Acetaminophen
25 Comparisons of iv Ibuprofen and iv Paracetamol During Bariatric Surgery Completed NCT02778958 Phase 4 paracetamol;ibuprofen
26 Study to Evaluate Weight-based Enoxaparin Dosing in Obese Medical Patients at Risk for DVT Completed NCT00585182 Phase 4 Enoxaparin 0.5 mg/kg once daily
27 Anidulafungin Pharmacokinetics Given as a Single Intravenous Dose to Obese Patients (ADOPT) Completed NCT02021123 Phase 4 Anidulafungin 100mg single dose iv
28 Pharmacokinetics of Propofol in Morbidly Obese Patients Completed NCT01536002 Phase 4 Propofol
29 Increased Cefazolin During Cesarean Delivery in Obese Population Completed NCT02049944 Phase 4 Cefazolin
30 Preoperative Condition in Giant Obese Patients Recruiting NCT02616003 Phase 4 Liraglutide
31 Aspiration Therapy in Asian Patients Recruiting NCT02881684 Phase 4
32 Aromatase Inhibitors and Weight Loss in Severely Obese Hypogonadal Male Veterans (Pilot) Recruiting NCT02959853 Phase 4 Anastrazole
33 DPE Technique in Labor Epidural for Morbidly Obese Women Recruiting NCT03074695 Phase 4 Dural puncture epidural (DPE);Standard Epidural (EPL)
34 Effect of Bile Acids and Bile Acid Sequstrants on GLP-1 Secretion After Roux-en-Y Gastric Bypass Recruiting NCT02952963 Phase 4 Chenodeoxycholic Acid;Colesevelam
35 Effects of Bile Acids and Bile Acid Sequestrants on GLP-1 Secretion After Roux-en-Y Gastric Bypass Recruiting NCT02876484 Phase 4 Colesevelam;Chenodeoxycholic Acid
36 Effect of Laparoscopic Sleeve Gastrectomy in the Morbidly Obese, Kidney Transplant Candidate Recruiting NCT01913392 Phase 4
37 Ketamine for Pain Relief in Bariatric Surgery Recruiting NCT03052673 Phase 4 Fentanyl;ketamine
38 Acute Effect of EPAP and Noninvasive Ventilation on Pulmonary Function and Lung Regional Ventilation on Bariatric Surgery Recruiting NCT02577744 Phase 4
39 Treatment of Periodontitis in Obese Individuals Recruiting NCT03103204 Phase 4
40 Metformin in Co-morbid Diabetes or Prediabetes and Serious Mental Illness Recruiting NCT02167620 Phase 4 Metformin;Placebo
41 Omega-3 Fatty Acids in Bariatric Gastric Bypass Surgery: Effect on Liver Volume, Immune Response and Erythrocyte Function Active, not recruiting NCT02206256 Phase 4 Omega-3 fatty acid capsules
42 Surgical Conditions During Laparoscopic Bariatric Surgery Active, not recruiting NCT02703909 Phase 4 Rocuronium
43 Gut Hormones as Mediators of Different Weight Loss Responses After Roux-en-Y Gastric Bypass Active, not recruiting NCT02374632 Phase 4
44 Treatment of Hypoglycemia Following Gastric Bypass Surgery Enrolling by invitation NCT02527993 Phase 4 Glucobay (acarbose);Januvia (sitagliptin);Verapamil HEXAL (verapamil);Victoza (liraglutide);Signifor (pasireotide)
45 Efficacy of Vitamin D Supplementation in Obese Children Enrolling by invitation NCT02956408 Phase 4
46 Liposomal Amphotericin B (AmBisome) Pharmacokinetics Given as a Single Intravenous Dose to Obese Patients (ASPEN) Not yet recruiting NCT02320604 Phase 4 Administration of study drug
47 Dosing Obese With Noxafil® Under a Trial (DONUT) Not yet recruiting NCT03246386 Phase 4 Posaconazole Injection [Noxafil] 300mg;Posaconazole Injection [Noxafil] 400mg
48 Study of Proton Pump Inhibitors (PPI) to Prevent Strictures After Gastric Bypass Surgery Withdrawn NCT00361985 Phase 4 Esomeprazole;Esomeprazole
49 Laparoscopic Sleeve Gastrectomy Plus Weight Watchers vs. Weight Watchers Alone in Underserved Minority Women Withdrawn NCT01929850 Phase 4
50 Stapled vs Hand Sewn Anastomosis in Roux en Y Gastric Bypass for Morbid Obesity: Randomized Clinical Trial Unknown status NCT02077517 Phase 3

Search NIH Clinical Center for Morbid Obesity

Cochrane evidence based reviews: obesity, morbid

Genetic Tests for Morbid Obesity

Genetic tests related to Morbid Obesity:

id Genetic test Affiliating Genes
1 Morbid Obesity 29

Anatomical Context for Morbid Obesity

MalaCards organs/tissues related to Morbid Obesity:

39
Liver, Kidney, Testes, Bone, Brain, Lung, Thyroid

Publications for Morbid Obesity

Articles related to Morbid Obesity:

(show top 50) (show all 774)
id Title Authors Year
1
Removal notice to The relationship between primary cesarean delivery skin incision type and wound complicationsA inA women with morbid obesity: Am J Obstet Gynecol 2014;210:319.e1-4. ( 28648694 )
2017
2
Long-Term Follow-Up of Autonomic and Enteric Measures in Patients Undergoing Vertical Banded Gastroplasty for Morbid Obesity. ( 28912907 )
2017
3
Decreased serum glicentin concentration in patients with severe and morbid obesity. ( 28661200 )
2017
4
Answer to the Letter to the Editor Concerning "Pharmacokinetics in Morbid Obesity: Influence of Two Bariatric Surgery Techniques on Paracetamol and Caffeine Metabolism". ( 28840448 )
2017
5
Plasma concentrations of caspofungin in a critically ill patient with morbid obesity. ( 28764793 )
2017
6
Effect of Weight Loss after Bariatric Surgery on Thyroid-Stimulating Hormone Levels in Patients with Morbid Obesity and Normal Thyroid Function. ( 28725979 )
2017
7
Letter in Reply to Arno et al. "Pharmacokinetics in Morbid Obesity: Influence of Two Bariatric Surgery Techniques on Paracetamol and Caffeine Metabolism". ( 28844097 )
2017
8
HIV Infection Is Not a Contraindication to Laparoscopic Sleeve Gastrectomy for Morbid Obesity. ( 28842820 )
2017
9
Modulation of SHBG binding to testosterone and estradiol by sex and morbid obesity. ( 28077498 )
2017
10
One-Anastomosis Gastric Bypass Versus Sleeve Gastrectomy for Morbid Obesity: a Systematic Review and Meta-analysis. ( 28681256 )
2017
11
Laparoscopic Sleeve Gastrectomy for Morbid Obesity in Patients After Orthotopic Liver Transplant: a Matched Case-Control Study. ( 28766265 )
2017
12
Prevalence of Micronutrient Deficiency in Patients with Morbid Obesity Before Bariatric Surgery. ( 28849358 )
2017
13
Folate and vitamin B12 status is associated with insulin resistance and metabolic syndrome in morbid obesity. ( 28780990 )
2017
14
Pulse-contour derived cardiac output measurements in morbid obesity: influence of actual, ideal and adjusted bodyweight. ( 28822023 )
2017
15
The usage of fasting glucose and glycated hemoglobin for the identification of unknown type 2 diabetes in high risk patients with morbid obesity. ( 28715238 )
2017
16
Zinc Deficiency after Gastric Bypass for Morbid Obesity: a Systematic Review. ( 27885534 )
2017
17
Prevalence and predictors of irritable bowel syndrome in patients with morbid obesity: a cross-sectional study. ( 28680646 )
2017
18
MYC amplification in angiosarcomas arising in the setting of chronic lymphedema of morbid obesity. ( 27686553 )
2017
19
Outcomes Experienced by Patients Presenting with Ventral Hernia and Morbid Obesity in a Surgical Clinic. ( 28822383 )
2017
20
Does Cardiorespiratory Fitness Attenuate the Adverse Effects of Severe/Morbid Obesity on Cardiometabolic Risk and Insulin Resistance in Children? A Pooled Analysis. ( 28939688 )
2017
21
Portomesenteric vein thrombosis after laparoscopic sleeve gastrectomy for morbid obesity. ( 28069786 )
2017
22
Epicardial fat thickness correlates with P-wave duration, left atrial size and decreased left ventricular systolic function in morbid obesity. ( 28739186 )
2017
23
Weighing the risks: Morbid obesity and diabetes are associated with increased risk of death on the liver transplant waiting list. ( 28727287 )
2017
24
The Socioeconomic Impact of Morbid Obesity and Factors Affecting Access to Obesity Surgery. ( 27473794 )
2016
25
Modulation of Irisin and Physical Activity on Executive Functions in Obesity and Morbid obesity. ( 27476477 )
2016
26
Chronic Abdominal Pain and Symptoms 5A Years After Gastric Bypass for Morbid Obesity. ( 28028658 )
2016
27
Morbid obesity is an independent risk factor forA postoperative renal dysfunction in young adults: a review of the American College ofA Surgeons National Surgical Quality Improvement Program database. ( 26941003 )
2016
28
Leptin receptor gene polymorphisms and morbid obesity in Mexican patients. ( 28096764 )
2016
29
Gastric bezoar after Roux-en-Y gastric bypass for morbid obesity: A case report. ( 27107501 )
2016
30
Morbid Obesity and Lumbar Fusion in Patients over 65 Years of Age: Complications, Readmissions, Costs, and Length of Stay. ( 27196019 )
2016
31
Effect of Malnutrition and Morbid Obesity on Complication Rates Following Primary Total Joint Arthroplasty. ( 27518294 )
2016
32
Management of Type 2 Diabetes in the Setting of Morbid Obesity: How Can Weight Gain Be Prevented or Reversed? ( 27092024 )
2016
33
Morbid Obesity in Total Hip Arthroplasty: Redefining Outcomes for Operative Time, Length of Stay, and Readmission. ( 26994650 )
2016
34
Patient Selection and Surgical Management of High-Risk Patients with Morbid Obesity. ( 27473799 )
2016
35
Evaluating the Obstetrical Implications of Antenatal Testing for Women with Morbid Obesity: Maternal and Fetal Outcomes of Increased Surveillance. ( 26960703 )
2016
36
The Association of Sleep Duration and Morbid Obesity in a Working Population: The Baptist Health South Florida Employee Study. ( 28026999 )
2016
37
A case report of chylous ascites after gastric bypass for morbid obesity. ( 27846453 )
2016
38
Whole-Exome Sequencing Suggests LAMB3 as a Susceptibility Gene for Morbid Obesity. ( 27431458 )
2016
39
The Correlation Of Increased Crp Levels With NFKB1 And TLR2 Polymorphisms In Case Of Morbid Obesity. ( 27507606 )
2016
40
Meta-analysis of hand-sewn versus mechanical gastrojejunal anastomosis during laparoscopic Roux-en-Y gastric bypass for morbid obesity. ( 27107663 )
2016
41
Marrow adipose tissue composition in adults with morbid obesity. ( 28043896 )
2016
42
Evaluation of laparoscopic sleeve gastrectomy compared with laparoscopic Roux-en-Y gastric bypass for people with morbid obesity: A systematic review and meta-analysis. ( 27453881 )
2016
43
Psychopathological behaviour and cognition in morbid obesity. ( 28029083 )
2016
44
Effects of the morbid obesity and skin incision choices on surgical outcomes in patients undergoing total abdominal hysterectomy. ( 28913120 )
2016
45
Early endometrial carcinoma therapy in morbid obesity: A retrospective study comparing open and laparoscopic. ( 27102329 )
2016
46
Relationship Between Vitamin D Deficiency and the Components of Metabolic Syndrome in Patients with Morbid Obesity, Before and 1A Year After Laparoscopic Roux-en-Y Gastric Bypass or Sleeve Gastrectomy. ( 27864670 )
2016
47
SY 06-3 ROLE OF SURGICAL TREATMENT OF MORBID OBESITY. ( 27642934 )
2016
48
The association between severity of King's Obesity Staging Criteria scores and treatment choice in patients with morbid obesity: a retrospective cohort study. ( 27980795 )
2016
49
The Role of Morbid Obesity in the Promotion of Metabolic Disruptions and Non-Alcoholic Steatohepatitis by Helicobacter Pylori. ( 27893763 )
2016
50
Predictors of Inadequate Weight Loss After Laparoscopic Gastric Bypass for Morbid Obesity. ( 27943095 )
2016

Variations for Morbid Obesity

ClinVar genetic disease variations for Morbid Obesity:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 PPARG NM_138712.3(PPARG): c.254C> A (p.Pro85Gln) single nucleotide variant Pathogenic rs1800571 GRCh37 Chromosome 3, 12422848: 12422848

Expression for Morbid Obesity

LifeMap Discovery
Genes differentially expressed in tissues of Morbid Obesity patients vs. healthy controls: 35
id Gene Description Tissue Up/Dn Fold Change (log2) P value
1 GAPDH glyceraldehyde-3-phosphate dehydrogenase Skeletal Muscle - 5.09 0.006
2 SLN sarcolipin Skeletal Muscle - 4.64 0.007
Search GEO for disease gene expression data for Morbid Obesity.

Pathways for Morbid Obesity

Pathways related to Morbid Obesity according to GeneCards Suite gene sharing:

(show all 13)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.38 ADRB3 CCK GHRL HCRT LEP LEPR
2 12.29 ADIPOQ FTO INS PPARG
3
Show member pathways
12.22 ADIPOQ INS LEP LEPR PPARG
5 11.55 INS LPL PPARG
6 11.51 ADIPOQ LEP LEPR
7 11.35 INS LEP LEPR
8 11.34 ADIPOQ INS LEP LPL PPARG
9 11.31 ADIPOQ FABP2 LPL PPARG
10 11.22 ADIPOQ INS LEP LPL PPARG RETN
11
Show member pathways
11.09 CRP LEP LEPR
12 10.94 ADIPOQ LEP PPARG
13 10.84 ADIPOQ LEP PPARG

GO Terms for Morbid Obesity

Cellular components related to Morbid Obesity according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.65 ADIPOQ ALB CCK CRP GHRL INS
2 extracellular region GO:0005576 9.4 ADIPOQ ALB CCK CRP GHRL HCRT

Biological processes related to Morbid Obesity according to GeneCards Suite gene sharing:

(show all 34)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.82 ADIPOQ CCK INS
2 positive regulation of MAPK cascade GO:0043410 9.82 ADRB3 INS LEP
3 response to nutrient GO:0007584 9.81 ADIPOQ LEP PPARG
4 response to insulin GO:0032868 9.77 LEP MC4R RETN
5 regulation of blood pressure GO:0008217 9.77 LEP MC3R PPARG
6 glucose metabolic process GO:0006006 9.73 ADIPOQ GHRL INS LEP
7 adenylate cyclase-modulating G-protein coupled receptor signaling pathway GO:0007188 9.72 ADRB3 MC3R MC4R
8 feeding behavior GO:0007631 9.69 HCRT MC4R PYY
9 response to cold GO:0009409 9.67 ADRB3 LPL PPARG
10 positive regulation of cellular protein metabolic process GO:0032270 9.66 ADIPOQ INS
11 regulation of fat cell differentiation GO:0045598 9.66 LEP PPARG
12 fatty acid oxidation GO:0019395 9.65 ADIPOQ PPARG
13 positive regulation of insulin receptor signaling pathway GO:0046628 9.65 INS LEP
14 sexual reproduction GO:0019953 9.63 LEP LEPR
15 adult feeding behavior GO:0008343 9.63 GHRL LEP
16 temperature homeostasis GO:0001659 9.63 ADRB3 FTO HCRT
17 negative regulation of lipid storage GO:0010888 9.62 CRP LEP
18 leptin-mediated signaling pathway GO:0033210 9.62 LEP LEPR
19 negative regulation of appetite GO:0032099 9.61 CCK LEP
20 diet induced thermogenesis GO:0002024 9.61 ADRB3 MC4R
21 negative regulation of acute inflammatory response GO:0002674 9.58 INS PPARG
22 response to nutrient levels GO:0031667 9.58 ADIPOQ LEP
23 negative regulation of gluconeogenesis GO:0045721 9.58 ADIPOQ INS LEPR
24 regulation of bone remodeling GO:0046850 9.57 LEP LEPR
25 glucose homeostasis GO:0042593 9.55 ADIPOQ INS LEP LEPR PPARG
26 regulation of brown fat cell differentiation GO:0090335 9.54 FTO LEP
27 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.54 ADIPOQ CRP PPARG
28 regulation of metabolic process GO:0019222 9.52 LEP MC4R
29 regulation of feeding behavior GO:0060259 9.5 LEPR MC3R MC4R
30 bone growth GO:0098868 9.48 LEP LEPR
31 negative regulation of feeding behavior GO:2000252 9.43 INS MC4R RETN
32 eating behavior GO:0042755 9.26 ADRB3 CCK HCRT LEP
33 energy reserve metabolic process GO:0006112 8.92 ADRB3 LEP LEPR MC4R
34 G-protein coupled receptor signaling pathway GO:0007186 10.1 ADRB3 GHRL INS MC3R MC4R PPARG

Molecular functions related to Morbid Obesity according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 fatty acid binding GO:0005504 9.37 ALB FABP2
2 neuropeptide binding GO:0042923 9.32 MC3R MC4R
3 melanocortin receptor activity GO:0004977 9.26 MC3R MC4R
4 hormone activity GO:0005179 9.17 ADIPOQ CCK GHRL INS LEP PYY
5 melanocyte-stimulating hormone receptor activity GO:0004980 9.16 MC3R MC4R
6 neuropeptide hormone activity GO:0005184 9.13 CCK HCRT PYY

Sources for Morbid Obesity

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....